Tumor Markers

Diagnosis

Tumor and Genetic Markers – Use for Specific Malignancy

Tumor and genetic markers may be useful in the diagnosis, treatment, monitoring and prognosis of specific tumors. The recommendations that follow are collected from multiple guideline sources. For specific information regarding use and interpretation of various markers and tests, consultation with a pathologist is highly advised. ARUP Laboratories may not offer all of the tests listed below; consult the Test tab for a list of tests offered.

Brain

Tumor Type

Marker

Recommended Use

Recommending Organizations

Oligodendroglioma

1p/19q deletion

Diagnosis

NSMO, NCCN

ESMO = European Society of Medical Oncology, NCCN = National Comprehensive Cancer Network

Childhood Tumors

Tumor Type

Marker

Recommended Use

Recommending Organizations

ALL

BCR-ABL1Diagnosis; prognosis; monitoringNCCN, WHO

TEL/AML1 (ETV6/RUNX1) t(12;21)(p13;q22)

Diagnosis; prognosis; monitoring

WHO

Hyperdiploidy (+4, +10, +17)

Diagnosis; prognosis; monitoring

WHO

MLL/11q23 rearrangements

Diagnosis; prognosis; monitoring

WHO

NeuroblastomaMYCN (N-MYC)PrognosisNCCN, ESMO
NCCN = National Comprehensive Cancer Network, WHO = World Health Organization, ESMO = European Society of Medical Oncology
Female Gynecologic/Genitourinary

Tumor Type

Marker

Recommended Use

Recommending Organizations

Bladder

BTA stat,
BTA TRAK,
NMP22,
UroVysion, ImmunoCyt

Monitoring

ACS, NACB, NCCN

Breast

 

BRCA1, BRCA2

Identifying high-risk patients

NCCN, NACB

CA 15-3, CA 27.29Monitoring advanced diseaseESMO, NACB, NCCN

CEA

Monitoring advanced disease

NACB, NCCN

ERBB2 (HER2/neu)

Predict response to Herceptin

ASCO, ESMO, NCCN, NACB

Prognosis

NCCN, NACB

Predict response to anthracyclines

ASCO, NCCN, NACB

MonitoringNACB

Estrogen, progesterone receptor

Predict response to antiestrogen therapy

ASCO, ESMO, NCCN, NACB

p53

Prognosis

ASCO (do not use alone), NCCN, NACB (do not use alone)

Cervical

HPV

Risk assessment

NCCN, NACB

SCC Ag

Monitoring

NACB

Gestational trophoblastic

Beta-hCG

Diagnosis

ACS, NACB, NCCN, ESMO

Monitoring

ACS, NACB, NCCN, ESMO

Ovarian

Epithelial

CA 125

Monitoring

ESMO, NACB, NCCN

Differential diagnosis in suspicious pelvic mass

NACB

Prognosis

NACB

Non-epithelial

CA 125Diagnosis; monitoringESMO
Inhibin

Granulosa cell tumors

InhibinDiagnosisESMO

Germ cell tumors

AFPDiagnosis; monitoringESMO
Beta-hCG
LDH
ASCO = American Society of Clinical Oncology, ESMO = European Society of Medical Oncology, NCCN = National Comprehensive Cancer Network, NACB = National Academy of Clinical Biochemistry, ACS = American Cancer Society
Gastrointestinal

Tumor Type

Marker

Recommended Use

Recommending Organizations*

Colorectal

BRAF V600E

Lynch syndrome risk assessment

NACB, NCCN

CEA

Monitoring

ASCO, NACB, ESMO, NCCN

Prognosis

ASCO, ACS, NCCN, NACB (if used with other prognostic features)

KRAS 

Predict response to EGFR inhibitors; prognosis

NCCN, ASCO

MLH1, MSH2, MSH6, PMS2

Lynch syndrome risk assessment

ESMO, NCCN, NACB

MSI/HNPCC

Colorectal and Lynch syndrome risk assessment

NCCN, NACB, ESMO

PIK3CA

Prediction of response to EGFR inhibitors

ESMO

Colorectal (familial adenomatous polyposis)

APC

Diagnosis

ESMO

Colorectal (MUTYH-associated polyposis)

MUTYH

Diagnosis

ESMO

Gastric

E-cadherinRisk factors in hereditary formsNCCN

GIST

CD117

Diagnosis

ESMO

cKIT

Diagnosis; response to tyrosine kinase inhibitors (TKI)

NCCN, ESMO

PDGFRA

Diagnosis; response to tyrosine kinase inhibitors (TKI)

NCCN, ESMO

Hepatic

AFP (in conjunction with ultrasound)

Monitoring; screening in high-risk patients

ACS, NCCN, ESMO, NACB, JSH

AFP-L3%

Monitoring; screening in high-risk patients; prognosis

NACB, JSH

DCP

Monitoring; screening in high-risk patients; prognosis

NACB, JSH

Pancreatic
(ductal adenocarcinoma)

CA 19-9

Diagnosis

NCCN

Monitoring

NCCN, ESMO, NACB, ASCO

Prognosis

NACB, NCCN

ACS = American Cancer Society, NCCN = National Comprehensive Cancer Network, ESMO = European Society of Medical Oncology, ASCO = American Society of Clinical Oncology, NACB = National Academy of Clinical Biochemistry, JSH=Japanese Society of Hepatology
*Organization also searched: American Gastroenterological Association

Head and Neck

Tumor Type

Marker

Recommended Use

Recommending Organizations

Squamous cell cancers

HPV

Prognosis

NCCN

EBV

Prognosis

NCCN

NCCN = National Comprehensive Cancer Network

Leukemia

Tumor Type

Marker

Recommended Use

Recommending Organizations

ALL

BCR-ABL1

Diagnosis; prognosis; monitoring

NACB, NCCN, WHO

c-Myc (MYC rearrangements [t(8;14)])

Diagnosis

NCCN, WHO

TCF3-PBX1 (E2A-PBX1) t(1;19)

Diagnosis; prognosis; monitoring

NCCN, WHO

TEL/AML1 (ETV6/RUNX1) t(12;21)(p13;q22)

Diagnosis; prognosis; monitoring

NCCN, WHO

IGH rearrangement

Diagnosis; prognosis; monitoring

NCCN, WHO

HOX11 t(10;14)(q24;q11)

Diagnosis; prognosis; monitoring

NCCN

HOX11L2 t(5;14)(q35;32)

Diagnosis; prognosis; monitoring

NCCN

MLL/11q23 rearrangements

Diagnosis; prognosis; monitoring

NCCN, WHO

TAL1 t(1;14)(p32;q11)

Diagnosis; prognosis; monitoring

NCCN

AML

MLL/11q23 rearrangements

Prognosis

ESMO, NCCN, WHO

RUNX1/RUNX1T1 (AML1/ETO) t(8;21)

Diagnosis; prognosis, monitoring

ESMO, NCCN

c-KIT

Prognosis in core binding AMLs  t(8;21) and inv(16)

NCCN, WHO

CBFB-MYH11 inv(16) t(16;16)

Diagnosis; prognosis

ESMO, NCCN, WHO, BSH

CEBPA

Prognosis in CN-AML

NCCN, WHO

FLT3-ITD

Prognosis in CN-AML

ESMO, BSH, NCCN, WHO

MLLT3-MLL t(9;11)

Prognosis in CN-AML

NCCN, WHO

NPM1

Prognosis in CN-AML

NCCN, WHO, ESMO

Philadelphia chromosome t(9;22) (BCR-ABL1)

Diagnosis; prognosis

NCCN, BSH, WHO

PML/RARA, t(15;17)

Diagnosis; prognosis

ESMO, NACB, NCCN, WHO, BSH

Monitoring

BSH, WHO, ESMO

CLL

IGHV mutation

Prognosis

NCCN, NACB, WHO

ZAP-70

Prognosis

NCCN, WHO

CML

BCR-ABL1

Diagnosis

ESMO, NCCN, BCSH, WHO

Prognosis

NCCN, ESMO, WHO

Monitoring

ESMO, NCCN, WHO

Eosinophilic leukemiasFIP1L1-PDGFRA region rearrangementsDiagnosis; prognosis; monitoringNCCN, ESMO
PDGFRBDiagnosis; prognosis; monitoringNCCN, ESMO

ESMO = European Society of Medical Oncology, NCCN = National Comprehensive Cancer Network, NACB = National Academy of Clinical Biochemistry, WHO = World Health Organization, BSH = British Society for Hematology, BCSH = British Committee for Standards in Hematology

Lung

Tumor Type

Marker

Recommended Use

Recommending 
Organizations*

Adenocarcinoma

EGFR, KRAS, ALK, ROS1

Determine eligibility for tyrosine kinase inhibitor (TKI) therapy

NCCN, ESMO

Mesothelioma

b72.3

Diagnosis

NCCN

Calretinin

Diagnosis

NCCN

CEA

Diagnosis

NCCN

CK 5,6

Diagnosis

NCCN

Soluble mesothelin related peptides (Mesomark)

Monitoring

IMIG, NCCN

TTF-1

Diagnosis

NCCN

WT-1

Diagnosis

NCCN

Non-small cell
(NSCLC)

CEA, SCC Ag

Monitoring; prognosis; detecting relapse

NACB

CYFRA 21-1 (CK19 fragment)

Monitoring; prognosis

NACB

Small cell
(SCLC)

Chromogranin A

Diagnosis; prognosis

NACB, NCCN

NSE

Diagnosis

NACB, NCCN

Monitoring

NACB

ACS = American Cancer Society, ASCO = American Society of Clinical Oncology, IMIG = International Mesothelioma Interest Group, NACB = National Academy of Clinical Biochemistry, NCCN = National Comprehensive Cancer Network
*Organizations also searched: American Thoracic Society (ATS), British Thoracic Society (BTS), American College of Chest Surgeons (ACCP)

Lymphoma

Tumor Type

Marker

Recommended Use

Recommending Organizations

B-cell and T/NK-cell

ALK rearrangements

Diagnosis; prognosis

NCCN, WHO

BIRC2-MALT1 (API2-MALT1) t(11;18)

Diagnosis of MALT subtype

NCCN, ESMO, WHO

Treatment planning

ESMO

IGH/BCL2

Diagnosis of follicular cell subtype

NCCN, WHO

IGH/CCND1

Diagnosis of mantle cell (MCL) subtype

NCCN, NACB, WHO

CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD14, CD15, CD19, CD20, CD21, CD23, CD33, CD45, CD52, CD56, CD57, CD64, CD79a, CD117 (c-KIT), CD138

Diagnosis; diagnosis of subtypes

NCCN, WHO

MYC rearrangements t(8;14)

Diagnosis of Burkitt lymphoma, double- and triple-hit lymphomas

NCCN, WHO

BCL6 (3q27)DiagnosisNCCN

Cyclin D1, SP4 t(11;14)

Diagnosis of MCL, multiple myeloma

NCCN, WHO

EBV-LMP1, EBV-EBER

Diagnosis of post-transplant lymphoproliferative disorder

NCCN, WHO

Granzyme B

Diagnosis

NCCN

Helicobacter pylori

Diagnosis of MALT

NCCN

HTLV

Risk assessment

NCCN, WHO

Ki-67 (MIB-1)

Diagnosis

NCCN, WHO

MUM1/IRF4

Diagnosis

NCCN

TCRG

Determine T-cell clonality

NCCN, WHO

 

TIA-1

Diagnosis

NCCN

NCCN = National Comprehensive Cancer Network, ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry, WHO=World Health Organization

Male Genitourinary

Tumor Type

Marker

Recommended Use

Recommending Organizations*

Bladder

BTA stat, BTA TRAK, NMP22, UroVysion, ImmunoCyt

Monitoring

ACS, NACB, NCCN

Germ cell (testicular)

Beta-hCG and AFP

Diagnosis

ASCO, EAU, ESMO, NACB, NCCN

Staging; prognosis

ASCO, EAU, ESMO,  NACB, NCCN

Monitoring

ASCO, EAU, ESMO, NACB, NCCN

LDHDiagnosisASCO, EAU, ESMO, NACB, NCCN
Staging; prognosisASCO, EAU, ESMO, NACB, NCCN
MonitoringASCO, EAU, ESMO, NACB, NCCN

Prostate

PCA3ScreeningNACB

PSA

Screening

ACS, AUA, EAU, NCCN

Staging; prognosis

AUA, EAU, ESMO, NCCN, NACB

Monitoring

AUA, EAU, ESMO, NCCN, NACB

Follow-up negative biopsy

NCCN, NACB

ASCO = American Society of Clinical Oncology, AUA = American Urological Association, EAU = European Association of Urologists, ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry, NCCN = National Comprehensive Cancer Network

Myeloma

Tumor Type

Marker

Recommended Use

Recommending Organizations

Multiple myeloma

t(4;14); t(14;16); del(17p); del(13q); t(11;14); 1q21 (amplification)

Prognosis

ESMO, NCCN, BCSH,WHO

ESMO = European Society of Medical Oncology, NCCN = National Comprehensive Cancer Network, BCSH = British Committee for Standards in Hematology, WHO = World Health Organization

Myeloproliferative Neoplasms

Tumor Type

Marker

Recommended Use

Recommending Organizations

Mast cell disordersKIT mutation (D816V)DiagnosisNCCN, WHO

Myeloproliferative neoplasms

JAK2, JAK2 exon 12, MPL W515K/L

Diagnosis

WHO

Myeloproliferative with associated eosinophilia

PDGFRA, PDGFRB, and FGFR1 rearrangements

Diagnosis

WHO

WHO = World Health Organization, NCCN = National Comprehensive Cancer Network
Neuroendocrine
Tumor TypeMarkerRecommended UseRecommending Organizations
Carcinoid5-HIAADiagnosisNCCN, ESMO, NACB
Monitoring for specific tumorNCCN, ESMO, NACB
Chromogranin AMonitoringNCCN
GastrinDiagnosis; monitoringNCCN
Pancreatic polypeptideDiagnosis; monitoringNCCN
SerotoninDiagnosisNACB, NCCN
GastrinomaGastrinDiagnosis; monitoringNCCN, ESMO, NACB
GlucagonomaGlucagonDiagnosis; monitoringNCCN, ESMO, NACB
InsulinomaC-peptideDiagnosis; monitoringNCCN
InsulinDiagnosis; monitoringNCCN
ProinsulinDiagnosis; monitoringNCCN, ESMO, NACB
Neuroendocrine tumorsChromogranin AMonitoringNACB, NCCN
RecurrenceNACB
CK (Cytokeratin)DiagnosisNCCN
Ki-67 (MIB-1)DiagnosisNCCN, ESMO
Pancreatic polypeptideDiagnosis; monitoringNCCN, ESMO, NACB
SynaptophysinDiagnosisNCCN, ESMO

Pancreatic neuroendocrine carcinoma

    

CalcitoninDiagnosis; monitoringNCCN
PTHDiagnosis; monitoringNCCN
PTH-related peptideDiagnosis; monitoringNCCN
PheochromocytomaCatecholaminesDiagnosis; monitoringNCCN, ESMO, NACB
MetanephrinesDiagnosis; monitoringNCCN, ESMO, NACB
PituitaryACTHDiagnosis; monitoringNCCN
Alpha subunitDiagnosis; monitoringNCCN
Growth hormoneDiagnosis; monitoringNCCN, ESMO, NACB
IGF-1Diagnosis; monitoringNCCN
LH/FSHDiagnosis; monitoringNCCN
ProlactinDiagnosis; monitoringNCCN
TSHDiagnosis; monitoringNCCN
SomatostatinomaSomatostatinDiagnosis; monitoringNCCN, ESMO
VIPomaVIPDiagnosis; monitoringNCCN, ESMO, NACB
NCCN = National Comprehensive Cancer Network, ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry
Skin

Tumor Type

Marker

Recommended Use

Recommending Organizations

Melanoma

BRAF

Assess response to tyrosine kinase inhibitors (TKI) in metastatic tumors

ESMO

c-Kit

Assess response to tyrosine kinase inhibitors (TKI) in metastatic tumors

ESMO, NCCN

NRAS

Assess response to tyrosine kinase inhibitors (TKI) in metastatic tumors

ESMO

S-100, HMB45 (gp100)

Diagnosis; usually used in combination

NACB

TA90-IC

Monitoring; prognosis

NACB

ACS = American Cancer Society, NACB = National Academy of Clinical Biochemistry, NCCN = National Comprehensive Cancer Network

Soft Tissue/Sarcomas

Tumor Type

Marker

Recommended Use

Recommending Organizations

Ewing sarcoma

EWSR1

Diagnosis

ESMO, NCCN

Kaposi sarcoma

HHV8

Diagnosis

NCCN

Rhabdomyosarcoma

FKHR

Diagnosis

NCCN

Synovial

SS18-SSX1, SSX2, SSX4

Diagnosis

NCCN

Myxoid/round cell

DDIT3

Diagnosis

NCCN

ESMO = European Society of Medical Oncology, NCCN = National Comprehensive Cancer Network

Thyroid/Parathyroid

Tumor Type

Marker

Recommended Use

Recommending Organizations

Hereditary forms

MEN1

Genetic risk assessment for MEN1

AACE, NCCN

RET

Genetic risk assessment for MEN2

AACE, NCCN

Medullary thyroid carcinomaCalcitoninDiagnosis; monitoringNCCN, AACE
PapillaryBRAF V600EDifferentiation of malignancy in indeterminate pathology; prognosisNCCN

Well-differentiated

Thyroglobulin

Diagnosis; monitoring

NCCN, AACE, ESMO

NCCN = National Comprehensive Cancer Network, AACE = American Association of Clinical Endocrinologists, NACB = National Academy of Clinical Biochemistry

Indications for Laboratory Testing

  • Tests generally appear in the order most useful for common clinical situations
  • Click on number for test-specific information in the ARUP Laboratory Test Directory
#-B
Test Name and NumberRecommended Use

1p/19q Deletion by FISH 2008604

Method: Fluorescence in situ Hybridization

Tumor(s): brain (oligodendroglioma)

Uses: diagnosis; prognosis

5-Hydroxyindoleacetic Acid (HIAA), Urine 0080420

Method: Quantitative High Performance Liquid Chromatography

Tumor(s): neuroendocrine (carcinoid)

Uses: diagnosis

Acute Lymphocytic Leukemia (ALL) Panel by FISH, Adult 2002647

Method: Fluorescence in situ Hybridization

Tumor(s): ALL

Uses: diagnosis; monitoring; prognosis

Probes include BCR/ABL1 t(9;22), MLL 11q23 rearrangement (partner not determined), t(1;19) translocation, IGH rearrangement (partner not determined), and MYC rearrangement (partner not determined)

Acute Lymphocytic Leukemia (ALL) Panel by FISH, Pediatric 2002719

Method: Fluorescence in situ Hybridization

Tumor(s): ALL

Uses: diagnosis; monitoring; prognosis

Probes include ETV6/RUNX1, BCR/ABL, CEP4, EP10, MLL probes

Acute Myelogenous Leukemia Panel by FISH 2002384

Method: Fluorescence in situ Hybridization

Tumor(s): AML 

Uses: diagnosis; prognosis; monitoring

Probes include RUNX1T1/RUNX1, MLL, and CBFB

Acute Myelogenous Leukemia (AML) with Myelodysplastic Syndrome (MDS) or Therapy Related AML, by FISH 2002653

Method: Fluorescence in situ Hybridization

Tumor(s): AML

Uses: diagnosis; prognosis; monitoring

Probes include -5/del(5q), -7/del(7q), 11q23 rearrangements (targets MLL)

ACTH by Immunohistochemistry 2003427

Method: Immunohistochemistry

Tumor(s): neuroendocrine (pituitary)

Uses: diagnosis

ALK (D5F3) with Interpretation by Immunohistochemistry 2007324

Method: Immunohistochemistry   

Tumor(s): lung (adenocarcinoma)

Uses: determine eligibility for ALK inhibitor therapy

ALK Gene Rearrangements in NSCLC for Crizotinib Eligibility by FISH 2006102

Method: Fluorescence in situ Hybridization

Tumor(s): lung

Uses: determine eligibility for ALK inhibitor therapy; not preferred test; preferred test is ALK (D5F3) by IHC

Alpha Fetoprotein, Serum (Tumor Marker) 0080428

Method: Electrochemiluminescent Immunoassay

Tumor(s): germ cell (testicular); hepatic

Uses: monitoring; screening in patients at high risk for HCC; diagnosis; staging and prognosis; detecting recurrence

Alpha Fetoprotein, Total and L3 Percent 0081208

Method: Quantitative Liquid Chromatography/Immunoassay

Tumor(s): hepatic

Uses: monitoring; screening in patients at high risk for HCC

Alpha Fetoprotein, CSF (Tumor Marker) 0020729

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): any tumors that secrete AFP with likely CSF metastases (eg, germ cell [testicular])

Uses: diagnosis; staging and prognosis

Alpha-1-Fetoprotein (AFP) by Immunohistochemistry 2003436

Method: Immunohistochemistry

Tumor(s): germ cell (testicular), hepatic

Uses: diagnosis

Anaplastic Lymphoma Kinase 1 (ALK-1) by Immunohistochemistry 2003439

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis  

Autoimmune Lymphoproliferative Profile 0095505

Method: Quantitative Flow Cytometry

Tumor(s): T-ALL

Uses: diagnosis

Components include α-​β+ & CD4-​ & CD8-​%; α-​β+ & CD4-​ & CD8-​#; CD5+ & CD20+%; CD5+ & CD20+#; CD3+ & HLA-​DR+%; and CD3+ & HLA-​DR+# 

B-Cell CD20 Expression 0092099

Method: Flow Cytometry

Tumor(s): lymphoma

Uses: diagnosis

B-Cell Clonality Screening (IgH and IgK) by PCR 2006193

Method: Polymerase Chain Reaction/Capillary Electrophoresis

Tumor(s): lymphoma

Uses: diagnosis

B Cell Specific Octamer Binding Protein-1 (BOB-1) by Immunohistochemistry 2003442

Method: Immunohistochemistry

Tumor(s): lymphoma (B-cell)

Uses: diagnosis    

BCL-2 by Immunohistochemistry 2004513

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis

BCL-6 by Immunohistochemistry 2003457

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis    

BCL6 (3q27) Gene Rearrangement by FISH 2010107

Method: Fluorescence in situ Hybridization

Tumor(s): lymphoma

Uses: diagnosis

BCR-ABL1 Mutation Analysis by Next Generation Sequencing  2008420

Method: Massive Parallel Sequencing

Tumor(s): leukemia (ALL, CML)

Uses: diagnosis; prognosis; monitoring

BCR-ABL1, Qualitative with Reflex to BCR-ABL1 Quantitative 2005010

Method: Reverse Transcription Polymerase Chain Reaction

Tumor(s): leukemia (ALL, CML)

Uses: diagnosis; prognosis; monitoring

Reflex – if the presence of either p210 or p190 BCR-ABL1 fusion is detected, then the appropriate quantitative test will be performed

BCR-ABL1, Major (p210), Quantitative 2005017

Method: Reverse Transcription/Quantitative Polymerase Chain Reaction

Tumor(s): leukemia (ALL, CML)

Uses: diagnosis; prognosis; monitoring

BCR-ABL1, Minor (p190), Quantitative 2005016

Method: Reverse Transcription/Quantitative Polymerase Chain Reaction

Tumor(s): leukemia (ALL, CML)

Uses: diagnosis; prognosis; monitoring

Beta-2 Microglobulin, Serum or Plasma 0080053

Method: Quantitative Immunoturbidimetry

Tumor(s): multiple myeloma

Uses: prognosis; monitoring

Beta-hCG, Quantitative (Tumor Marker) 0070029

Method: Chemiluminescent Immunoassay

Tumor(s): non-epithelial ovarian; gestational trophoblastic; germ cell (testicular)

Uses: diagnosis; monitoring; recurrence

Beta-hCG, Quantitative (Tumor Marker), CSF 0020730

Method: Quantitative Electrochemiluminescent Immunoassay

Tumor(s): non-epithelial ovarian; gestational trophoblastic; germ cell (testicular)

Uses: diagnosis

BF-1 by Immunohistochemistry 2003466

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis  

BIRC2-MALT1 (AP12-MALT1) Translocation, t(11;18) by RT-PCR 0055691

Method: Reverse Transcription Polymerase Chain Reaction

Tumor(s): lymphoma

Uses: diagnosis of MALT subtype  

Bladder Tumor Associated Antigen 8100500

Method: Qualitative Immunoassay

Tumor(s): bladder

Uses: monitoring; early detection

BRAF Codon 600 Mutation Detection by Pyrosequencing 2002498

Method: Polymerase Chain Reaction/Pyrosequencing

Tumor(s): thyroid/parathyroid; Lynch syndrome

Uses: diagnosis; prognosis; risk assessment

BRAF Codon 600 Mutation with Reflex to MLH1 Promoter Methylation 0051750

Method: Polymerase Chain Reaction/Pyrosequencing

Tumor(s): Lynch syndrome

Uses: differentiate Lynch syndrome from sporadic microsatellite unstable (MSI) colorectal cancer

Reflex – if BRAF codon 600 Mutation Detection is negative, then MLH1 Promoter Methylation will be added

BRAF V600E by Immunohistochemistry 2008710

Method: Immunohistochemistry

Tumor(s): colorectal; melanoma; thyroid

Uses: diagnosis

BRAF V600E by Allele-Specific PCR, Fine Needle Aspirate 2006516

Method: Polymerase Chain Reaction

Tumor(s): melanoma; thyroid; non-small cell lung cancer (NSCLC)

Uses: assess for responsiveness to BRAF inhibitor therapy; differential diagnosis in indeterminate thyroid histology

BRAF V600E Mutation Detection in Hairy Cell Leukemia by Real-Time PCR, Quantitative 2007132

Method: Polymerase Chain Reaction

Tumor(s): hairy cell leukemia

Uses: diagnosis; monitoring

Breast 2 (GCDFP-15) by Immunohistochemistry 2003472

Method: Immunohistochemistry

Tumor(s): breast

Uses: diagnosis

Breast Carcinoma b72.3 by Immunohistochemistry 2003445

Method: Immunohistochemistry

Tumor(s): breast

Uses: diagnosis

C-D
Test Name and NumberRecommended Use

c-MET by Immunohistochemistry 2008652

Method: Immunohistochemistry

Tumor(s): lung

Uses: diagnosis

C-Peptide, Serum or Plasma 0070103

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): neuroendocrine (insulinoma)

Uses: diagnosis

Calcitonin 0070006

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): neuroendocrine (medullary thyroid carcinoma)

Uses: diagnosis; monitoring

Calcitonin by Immunohistochemistry 2003481

Method: Immunohistochemistry

Tumor(s): medullary thyroid; pancreatic neuroendocrine

Uses: diagnosis

Calcium, Serum or Plasma 0020027

Method: Quantitative Spectrophotometry

Tumor(s): parathyroid

Uses: diagnosis; monitoring

Caldesmon by Immunohistochemistry 2003484

Method: Immunohistochemistry

Tumor(s): sarcoma

Uses: diagnosis

Calretinin by Immunohistochemistry 2003490

Method: Immunohistochemistry

Tumor(s): mesothelioma

Uses: diagnosis

Cancer Antigen 125 0080462

Method: Quantitative Electrochemiluminescent Immunoassay

Tumor(s): ovarian

Uses: monitoring; differential diagnosis; prognosis

Cancer Antigen 125 by Immunohistochemistry 2003478

Method: Immunohistochemistry

Tumor(s): ovarian

Uses: diagnosis

Cancer Antigen 27.29 0080392

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): breast

Uses: monitor advanced disease

Cancer Antigen-Breast (CA 15-3) 0080464

Method: Quantitative Electrochemiluminescent Immunoassay

Tumor(s): breast

Uses: monitor advanced disease

Cancer Antigen-GI (CA 19-9) 0080461

Method: Quantitative Electrochemiluminescent Immunoassay

Tumor(s): pancreatic (ductal adenocarcinoma)

Uses: diagnosis; monitoring; prognosis

Cancer Antigen-GI (CA 19-9), Body Fluid 0020746

Method: Quantitative Electrochemiluminescent Immunoassay

Tumor(s): pancreatic (ductal adenocarcinoma)

Uses: diagnosis; monitoring; prognosis

Carcinoembryonic Antigen 0080080

Method: Quantitative Eletrochemiluminescent Immunoassay

Tumor(s): variety of tumors

Uses: monitoring; prognosis

Carcinoembryonic Antigen, Fluid 0020742

Method: Quantitative Eletrochemiluminescent Immunoassay

Tumor(s): variety of tumors

Uses: diagnosis; monitoring; prognosis

Carcinoembryonic Antigen, Monoclonal (CEA M) by Immunohistochemistry 2003824

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Carcinoembryonic Antigen, Polyclonal (CEA P) by Immunohistochemistry 2003827

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Caspase-3 by Immunohistochemistry 2003496

Method: Immunohistochemistry

Tumor(s): breast cancer

Uses: prognosis

Catecholamines Fractionated by LC-MS/MS, Urine Free 0080407

Method: Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Tumor(s): neuroendocrine (pheochromocytoma, neuroblastoma)

Uses: diagnosis; monitoring 

Catecholamines Fractionated, Plasma 0080216

Method: Quantitative High Performance Liquid Chromatography

Tumor(s): neuroendocrine (pheochromocytoma, neuroblastoma)

Uses: diagnosis; monitoring 

CBFB-MYH11, inv(16) by RT-PCR 0092209

Method: Reverse Transcription Polymerase Chain Reaction

Tumor(s): leukemia (AML)

Uses: diagnosis; prognosis  

CD2 by Immunohistochemistry 2003505

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD3 by Immunohistochemistry 2003508

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD4 by Immunohistochemistry 2003511

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD5 by Immunohistochemistry 2003514

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD7 by Immunohistochemistry 2003517

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD8 by Immunohistochemistry 2003520

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis 

CD10 (CALLA) by Immunohistochemistry 2003523

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD14 by Immunohistochemistry 2003526

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD15, Leu M1 by Immunohistochemistry 2003529

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD19 by Immunohistochemistry 2005114

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD20, L26 by Immunohistochemistry 2003532

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD23 by Immunohistochemistry 2003541

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD25 by Immunohistochemistry 2003544

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis 

CD30 (Ki-1) by Immunohistochemistry 2003547

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis 

CD33 by Immunohistochemistry 2003553

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis   

CD42b by Immunohistochemistry 2003565

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

CD43, L60 (Leu 22) by Immunohistochemistry 2003568

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis

CD44 by Immunohistochemistry 2003571

Method: Immunohistochemistry

Tumor(s): neuroendocrine (neuroblastoma)

Uses: diagnosis

CD45 by Immunohistochemistry 2003574

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis      

CD52 (CAMPATH-1) by Immunohistochemistry 2003586

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis

CD56 (NCAM) by Immunohistochemistry 2003589

Method: Immunohistochemistry

Tumor(s): pulmonary small cell carcinomas

Uses: diagnosis       

CD57 by Immunohistochemistry 2003592

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis    

CD61 (Platelet Glycoprotein IIIA) by Immunohistochemistry 2003595

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

CD68, KP1 by Immunohistochemistry 2003598

Method: Immunohistochemistry

Tumor(s): glioma; lymphoma

Uses: diagnosis

CD79A by Immunohistochemistry 2003800

Method: Immunohistochemistry

Tumor(s): B-ALL

Uses: diagnosis     

CD117 (c-Kit) by Immunohistochemistry 2003806

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis; prognosis; assess response to TKI

CD138 (Syndecan-1) by Immunohistochemistry 2003812

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis  

CDK4 by Immunohistochemistry 2005534

Method: Immunohistochemistry

Tumor(s): sarcoma

Uses: diagnosis

CDX2 by Immunohistochemistry 2003821

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

CEBPA Mutation Detection 2004247

Method: Polymerase Chain Reaction/Sequencing

Tumor(s): leukemia (AML)

Uses: prognosis

Chromogranin A 0080469

Method: Quantitative Enzyme Immunoassay

Tumor(s): variety of tumors

Uses: diagnosis; monitoring; prognosis

Chromogranin A by Immunohistochemistry 2003830

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Chromosome Analysis, Bone Marrow 2002292

Method: Giemsa Band

Tumor(s): variety of tumors

Uses: diagnosis; prognosis; monitoring

Chromosome Analysis, Bone Marrow with Reflex to Genomic Microarray 2007130

Method: Giemsa Band/Genomic Microarray (Oligo-SNP array)

Tumor(s): variety of tumors

Uses: diagnosis

Chromosome Analysis, Leukemic Blood 2002290

Method: Giemsa Band

Tumor(s): leukemia

Uses: diagnosis; prognosis

Chromosome Analysis, Solid Tumor 2002296

Method: Giemsa Band

Tumor(s): any solid tumor

Uses: diagnosis; prognosis; monitoring

Chromosome FISH, CLL Panel 2002295

Method: Fluorescence in situ Hybridization

Tumor(s): CLL

Use: diagnosis; prognosis; monitoring

Panel includes ATM deletion, D13S319 deletion, Trisomy 12, TP53 deletion  

Chromosome FISH, Interphase 2002298

Method: Fluorescence in situ Hybridization

Tumor(s): variety of tumors

Uses: diagnosis; prognosis; monitoring

Specific FISH probes must be requested – ARUP Oncology FISH Probes menu

Circulating Tumor Cell Count 0093399

Method: Immunomagnetic Separation/Immunofluorescent Stain/Computer Assisted Analysis

Tumor(s): variety of tumors

Uses: monitoring; prognosis

Cyclin D1, SP4 by Immunohistochemistry 2003842

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis of MCL subtype  

CYFRA 21-1 (Cytokeratin 19 Fragment), Serum 0081344

Method: Quantitative Enzyme-Linked Immunosorbent Assay

Tumor(s): lung

Uses: prognosis; monitoring

Cytogenomic Molecular Inversion Probe Array, FFPE Tissue – Oncology 2010229

Method: Molecular Inversion Probe Array

Tumor(s): variety

Uses: diagnosis

Cytogenomic SNP Microarray – Oncology 2006325

Method: Genomic Microarray (Oligo-SNP Array)

Tumor(s): CLL; AML; ALL; MDS/AML

Use: diagnosis; prognosis; monitoring

Cytokeratin 19 (CK 19) by Immunohistochemistry 2003845

Method: Immunohistochemistry

Tumor(s): variety of tumors   

Uses: diagnosis

Cytokeratin 20 (CK 20) by Immunohistochemistry 2003848

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Cytokeratin 5,6 (CK 5,6) by Immunohistochemistry 2003851

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Cytokeratin 7 (CK 7) by Immunohistochemistry 2003854

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Cytokeratin 8,18 Low Molecular Weight (CAM 5.2) by Immunohistochemistry 2003493

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Cytology, Body Cavity Fluid 8209701

Method: Microscopy

Tumor(s): variety of tumors

Uses: diagnosis

Cytology, Breast Nipple Secretion 8209700

Method: Microscopy

Tumor(s): breast

Uses: diagnosis

Cytology, Bronchoalveolar Lavage, Malignancy 8280005

Method: Microscopy

Tumor(s): lung

Uses: diagnosis

Cytology, Cerebrospinal Fluid 8209703

Method: Microscopy

Tumor(s): central nervous system

Uses: diagnosis

Cytology, Fine Needle Aspirate 8209706

Method: Microscopy

Tumor(s): variety of tumors

Uses: diagnosis

Cytology, Gastrointestinal 8209709

Method: Microscopy

Tumor(s): gastrointestinal

Uses: diagnosis

Cytology, Oral 8209710

Method: Microscopy

Tumor(s): oral

Uses: diagnosis

Cytology, Pulmonary 8209702

Method: Microscopy

Tumor(s): lung

Uses: diagnosis

Cytology, SurePath Liquid-Based Pap Test 2000134

Method: Microscopy

Tumor(s): cervical

Uses: risk assessment

Cytology, SurePath Liquid-Based Pap Test and Human Papillomavirus (HPV), High Risk by Hybrid Capture (for routine co-testing in women over 30) 2000133

Method: Microscopy/Qualitative Nucleic Acid Probe

Tumor(s): cervical

Uses: risk assessment

UUHSC testing only

Cytology, SurePath Liquid-Based Pap Test with Reflex to Human Papillomavirus (HPV), High Risk by Hybrid Capture 2000135

Method: Microscopy/Qualitative Nucleic Acid Probe

Tumor(s): cervical

Uses: risk assessment

Cytology, ThinPrep Pap Test 2000137

Method: ThinPrep® 2000 System/Routine Cytopathologic Evaluation

Tumor(s): cervical

Uses: risk assessment

Cytology, ThinPrep Pap Test with Reflex to Human Papillomavirus (HPV), High Risk E6/E7 mRNA by Transcription-Mediated Amplification (TMA) 2000138

Method: Microscopy/Qualitative Transcription-mediated Amplification

Tumor(s): cervical

Uses: risk assessment

Reflex – if ThinPrep Pap Test is interpreted as atypical squamous cells of undetermined significance (ASC-US), then Human Papillomavirus (HPV), High Risk, E6/E7 mRNA by Transcription-Mediated Amplification (TMA) will be added

Cytology, ThinPrep Pap Test and Human Papillomavirus (HPV), High Risk, E6/E7 mRNA by Transcription-Mediated Amplification (TMA) (for routine co-testing in women over 30) 2000136

Method: Microscopy/Qualitative Transcription-mediated Amplification

Tumor(s): cervical

Uses: risk assessment

Cytology, Urologic 8209704

Method: Microscopy

Tumor(s): bladder; renal

Uses: diagnosis

Cytology, Vitreous Fluid 8209715

Method: Microscopy

Tumor(s): ocular

Uses: diagnosis

D2-40 by Immunohistochemistry 2003857

Method: Immunohistochemistry

Tumor(s): central nervous system; mesothelioma

Uses: diagnosis

DDIT3 (CHOP) (12q13) Gene Rearrangement by FISH 2007223

Method: Fluorescence in situ Hybridization

Tumor(s): sarcoma

Uses: differential diagnosis between lipoblastoma and myxoid/round cell liposarcoma

Des-gamma-carboxy Prothrombin 0081312

Method: Quantitative Liquid Chromatography/Immunoassay

Tumor(s): HCC

Uses: monitoring; screening in high-risk patients

Desmin by Immunohistochemistry 2003863

Method: Immunohistochemistry

Tumor(s): sarcomas

Uses: diagnosis

DNA Content/Cell Cycle Analysis, Colon 0095140

Method: Quantitative Flow Cytometry

Tumor(s): colon

Uses: diagnosis

DNA Content/Cell Cycle Analysis – Ploidy and S-Phase 0095155

Method: Quantitative Flow Cytometry

Tumor(s): variety of tumors

Uses: diagnosis

DOG1 by Immunohistochemistry 2010168

Method: Immunohistochemistry

Tumor(s): gastrointestinal

Uses: diagnosis

E-H
Test Name and NumberRecommended Use

E-Cadherin by Immunohistochemistry 2003869

Method: Immunohistochemistry

Tumor(s):  variety of tumors

Uses: diagnosis

EGFR Mutation Detection by Pyrosequencing 2002440

Method: Polymerase Chain Reaction/Pyrosequencing

Tumor(s): pulmonary adenocarcinomas

Uses: determine TKI eligibility

EGFR Gene Amplification by FISH 2008605

Method: Fluorescence in situ Hybridization

Tumor(s): variety of tumors

Uses: prognosis; therapeutic decisions

Eosinophilia Panel by FISH 2002378

Method: Fluorescence in situ Hybridization

Tumor(s): AML; MPN

Uses: diagnosis; prognosis

Probes include PDGFRAPDGFRB, FGFR1, and CBFB

Epithelial Membrane Antigen (EMA) by Immunohistochemistry 2003872

Method: Immunohistochemistry

Tumor(s): sarcoma

Uses: diagnosis

Epithelial-Related Antigen, MOC-31 by Immunohistochemistry 2003875

Method: Immunohistochemistry

Tumor(s): lung

Uses: diagnosis

Epstein-Barr Virus (EBV) By in situ Hybridization, Paraffin 2002902

Method: In situ Hybridization

Tumor(s): head and neck; lymphoma

Uses: diagnosis  

ERBB2 (HER2/neu) (4B5) by Immunohistochemistry, Tissue with Reflex to Dual ISH if 2+ 2007782

Method: Immunohistochemistry

Tumor(s): breast

Uses: prognosis; predict response to Herceptin

Test is graded 0-3 in a semiquantitative manner

Reflex – if ERBB2 (HER2/neu) (4B5) result is 2+, then ERBB2 (HER2/neu) Gene Amplification by Dual In Situ Hybridization will be added

ERBB2 (HER2/neu) (4B5) by Immunohistochemistry, Tissue with Reflex to FISH if 2+ 2002217

Method: Immunohistochemistry

Tumor(s): breast

Uses: prognosis; predict response to Herceptin

Test is graded 0-3 in a semiquantitative manner

Reflex – if ERBB2 (HER2/neu) (4B5) result is 2+, then ERBB2 (HER2/neu) Gene Amplification by FISH will be added

ERBB2 (HER2/neu) (4B5) with Interpretation by Immunohistochemistry, Tissue 2002218

Method: Immunohistochemistry

Tumor(s): breast

Uses: prognosis; predict response to Herceptin

Test is graded 0-3 in a semiquantitative manner

ERBB2 (HER2/neu) Gene Amplification by Dual in-situ Hybridization 2007410

Method: Dual in situ Hybridization

Tumor(s): breast

Uses: prognosis; predict response to Herceptin

ERBB2 (HER2/neu) Gene Amplification by FISH, Tissue 2008603

Method: Fluorescence in situ Hybridization

Tumor(s): breast

Uses: prognosis; predict response to Herceptin

ERBB2 (HER2/neu) Gene Amplification by PCR 0049390

Method: Polymerase Chain Reaction

Tumor(s): breast

Uses: prognosis; predict response to Herceptin (resolve discrepancies between FISH/ISH and IHC results)

ERBB2 (HER2/neu) (HercepTest) by Immunohistochemistry, Tissue with Reflex to Dual ISH if 2+ 2007785

Method: Immunohistochemistry

Tumor(s): breast

Uses: prognosis; predict response to Herceptin

Test is graded 0-3 in a semiquantitative manner

Reflex – if ERBB2 (HercepTest) result is 2+, then ERBB2 (HER2/neu) Gene Amplification by Dual In Situ Hybridization will be added

ERBB2 (HER2/neu) (HercepTest) by Immunohistochemistry, Tissue with Reflex to FISH if 2+ 0049178

Method: Immunohistochemistry

Tumor(s): breast

Uses: prognosis; predict response to Herceptin

Reflex – if ERBB2 (HercepTest) result is 2+, then ERBB2 (HER2/neu) Gene Amplification by FISH will be added

ERBB2 (HER2/neu) (HercepTest) with Interpretation by Immunohistochemistry, Tissue 0049174

Method: Immunohistochemistry

Tumor(s): breast

Uses: prognosis; predict response to Herceptin

Test is graded 0-3 in a semiquantitative manner

Esterase Stain, Nonspecific 0049050

Method: Cytochemical Stain

Tumor(s): leukemia

Uses: diagnosis

Estrogen/Progesterone Receptor with Interpretation by Immunohistochemistry 0049210

Method: Immunohistochemistry

Tumor(s): breast

Uses: predict response to antiestrogen therapy

Estrogen Receptor (ER) by Immunohistochemistry 2004516

Method: Immunohistochemistry

Tumor(s): breast

Uses: predict response to antiestrogen therapy

ETV6-RUNX1 (TEL-AML1) Translocation, t(12;21) by RT-PCR 0056008

Method: Reverse Transcription Polymerase Chain Reaction

Tumor(s): ALL

Uses: diagnosis; prognosis  

Ewing Sarcoma (O13) by Immunohistochemistry 2004055

Method: Immunohistochemistry

Tumor(s): Ewing sarcoma

Uses: diagnosis

EWSR1-FLI1 and EWSR1-ERG Translocations by RT-PCR 0051220

Method: Reverse Transcription Polymerase Chain Reaction

Tumor(s): Ewing sarcoma

Uses: diagnosis

EWSR1 (22q12) Gene Rearrangement by FISH 2007225

Method: Fluorescence in situ Hybridization

Tumor(s): Ewing sarcoma

Uses: diagnosis

FGFR2 Gene Amplification by FISH 2007099

Method: Fluorescence in situ Hybridization

Tumor(s): breast

Uses: predict responsiveness to FGFR inhibitors (dovitinib)

FLT3 Mutation Detection by PCR 2005400

Method: Qualitative Polymerase Chain Reaction/Capillary Electrophoresis

Tumor(s): AML

Uses: prognosis

Friend Leukemia Integration-1 (Fli-1) by Immunohistochemistry 2003887

Method: Immunohistochemistry

Tumor(s): sarcomas

Uses: diagnosis

FOXO1 (FKHR) (13q14) Gene Rearrangement by FISH  2001497

Method: Fluorescence in situ Hybridization

Tumor(s): alveolar rhabdomyosarcoma

Uses: diagnosis

Gastrointestinal Stromal Tumor Mutation 2002674

Method: Polymerase Chain Reaction/Sequencing

Tumor(s): GIST

Uses: diagnosis

Panel includes KIT and PDGFRA

Gastrin 0070075

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): neuroendocrine (gastrinoma, carcinoid)

Uses: diagnosis; monitoring

Gastrin by Immunohistochemistry 2003896

Method: Immunohistochemistry

Tumor(s): neuroendocrine (gastrinoma, carcinoid)

Uses: diagnosis; monitoring

Glial Fibrillary Acidic Protein (GFAP) by Immunohistochemistry 2003899

Method: Immunohistochemistry

Tumor(s): central nervous system; GIST

Uses: diagnosis

Glucagon 0099165

Method: Quantitative Radioimmunoassay

Tumor(s): neuroendocrine (glucagonoma)

Uses: diagnosis; monitoring

Granzyme B by Immunohistochemistry 2007173

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis

Growth Hormone 0070080

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): neuroendocrine (pituitary)

Uses: diagnosis; monitoring

Growth Hormone by Immunohistochemistry 2003929

Method: Immunohistochemistry

Tumor(s): neuroendocrine (pituitary)

Uses: diagnosis; monitoring

HBME-1 (Mesothelial Cell) by Immunohistochemistry 2003914

Method: Immunohistochemistry

Tumor(s): mesothelioma

Uses: diagnosis

Helicobacter pylori by Immunohistochemistry 2003941

Method: Immunohistochemistry

Tumor(s): MALT

Uses: diagnosis

Hepatocellular Carcinoma Tumor Marker Panel 0081326

Method: Quantitative Liquid Chromatography/Immunoassay

Tumor(s): hepatocellular

Uses: screening; monitoring

Panel includes AFP total, AFP-L3%, and DCP

HER2/neu Quantitative by ELISA 2004672

Method: Quantitative Enzyme-Linked Immunosorbent Assay

Tumor(s): breast

Uses: prognosis

Herpes Virus 8 by Immunohistochemistry 2003932

Method: Immunohistochemistry

Tumor(s): Kaposi sarcoma

Uses: diagnosis

HNPCC/Lynch Syndrome Deletion/Duplication 2001728

Method: Polymerase Chain Reaction/Multiplex Ligation-dependent Probe Amplification

Tumor(s): Lynch syndrome

Uses: diagnosis

Order only if sequencing has been performed; both sequencing and deletion/duplication testing are necessary to detect all pathogenic mutations in MMR genes

HNPCC/Lynch Syndrome (MLH1) Sequencing and Deletion/Duplication 0051650

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Tumor(s): MSI carcinoma

Uses: diagnosis

HNPCC/Lynch Syndrome (MSH2) Sequencing and Deletion/Duplication 0051654

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Tumor(s): MSI carcinoma

Uses: diagnosis

HNPCC/Lynch Syndrome (MSH6) Sequencing and Deletion/Duplication 0051656

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Tumor(s): MSI carcinoma

Uses: diagnosis

HNPCC/Lynch Syndrome (PMS2) Sequencing and Deletion/Duplication 0051737

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Tumor(s): MSI carcinoma

Uses: diagnosis

Homovanillic Acid (HVA), Urine 0080422

Method: Qualitative High Performance Liquid Chromatography

Tumor(s): neuroblastoma tumor marker

Uses: diagnosis; monitoring

Human Chorionic Gonadotropin (Beta-hCG) by Immunohistochemistry 2003920

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Human Epididymis Protein 4 (HE4) 2003020

Method: Quantitative Enzyme Immunoassay

Tumor(s): ovarian

Uses: diagnosis; monitoring; prognosis

Human Papillomavirus (HPV) Genotypes 16 and 18/45, by Transcription-Mediated Amplification (TMA), ThinPrep 2007894

Method: Transcription-Mediated Amplification

Tumor(s): cervical

Uses: risk assessment

Human Papillomavirus (HPV), High Risk, by Transcription-Mediated Amplification (TMA), ThinPrep 2007893

Method: Transcription-Mediated Amplification

Tumor(s): cervical

Uses: risk assessment

Human Papillomavirus (HPV), High Risk by Hybrid Capture, SurePath 0060744

Method: Qualitative Nucleic Acid Probe

Tumor(s): cervical

Uses: risk assessment

Human Papillomavirus (HPV), High Risk by Hybrid Capture, Cervical Brush 0065999

Method: Qualitative Nucleic Acid Probe

Tumor(s): cervical

Uses: risk assessment

Human Papillomavirus (HPV), High Risk by Hybrid Capture, ThinPrep 2008404

Method: Qualitative Nucleic Acid Probe

Tumor(s): cervical

Uses: risk assessment

Human Papillomavirus (HPV), High Risk in situ Hybridization, Paraffin 2002899

Method: In situ Hybridization

Tumor(s): head and neck; cervical

Uses: risk assessment

Human Placental Lactogen (HPL) by Immunohistochemistry 2003938

Method: Immunohistochemistry

Tumor(s): gestational trophoblastic

Uses: diagnosis

Human T-Lymphotrophic Virus Types I/II Antibodies, Western Blot 0020642

Method: Qualitative Western Blot

Tumor(s): leukemia; lymphoma

Uses: diagnosis

I-M
Test Name and NumberRecommended Use

IDH1 and IDH2 Mutation Analysis, exon 4 2006444

Method: Polymerase Chain Reaction/Sequencing

Tumor(s): AML; gliomas

Uses: prognosis

IDH1 R132H by Immunohistochemistry 2005857

Method: Immunohistochemistry

Tumor(s): gliomas

Uses: diagnosis

IDH1 R132H Point Mutation with Interpretation by Immunohistochemistry 2007357

Method: Immunohistochemistry

Tumor(s): gliomas

Uses: diagnosis

IGF-1 (Insulin-Like Growth Factor) 0070125

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): neuroendocrine

Uses: diagnosis

IGH-BCL2 Fusion, t(14;18) by FISH 2001536

Method: Fluorescence in situ Hybridization

Tumor(s): lymphoma

Uses: diagnosis

IGH-BCL2 (BCL-2/JH) Translocation, t(14;18) by PCR 0055616

Method: Polymerase Chain Reaction

Tumor(s): lymphoma

Uses: diagnosis

IGH-CCND1 (BCL-1/JH) Translocation, t(11;14) by PCR 0055557

Method: Polymerase Chain Reaction

Tumor(s): lymphoma

Uses: diagnosis  

IGH-CCND1 Fusion, t(11;14) by FISH 2007226

Method: Fluorescence in situ Hybridization

Tumor(s): lymphoma 

Uses: diagnosis   

IGH-MYC Fusion t(8;14) by FISH 2001538

Method: Fluorescence in situ Hybridization

Tumor(s): lymphoma

Uses: diagnosis

IGHV Mutation Analysis by Sequencing 0040227

Method: Polymerase Chain Reaction/Sequencing

Tumor(s): CLL

Uses: determine risk group

Immunofixation Electrophoresis Gel 0050272

Method: Qualitative Immunofixation Electrophoresis

Tumor(s): multiple myeloma

Uses: diagnosis

Inhibin A (Dimer) 0070137

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): ovarian

Uses: diagnosis; monitoring

Inhibin B 0070413

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): ovarian

Uses: diagnosis; monitoring

Inhibin by Immunohistochemistry 2003969

Method: Immunohistochemistry

Tumor(s): ovarian, central nervous system

Uses: diagnosis

INI1 (BAF47) by Immunohistochemistry 2003448

Method: Immunohistochemistry

Tumor(s): sarcomas

Uses: diagnosis

Insulin, Fasting 0070063

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): neuroendocrine (insulinoma)

Uses: diagnosis

JAK2 Exon 12 Mutation Analysis by PCR 2002357

Method: Polymerase Chain Reaction

Tumor(s): MPN

Uses: diagnosis

JAK2 Gene, V617F Mutation, Qualitative 0051245

Method: Polymerase Chain Reaction

Tumor(s): MPN

Uses: screening

JAK2 Gene, V617F Mutation, Quantitative 0040168

Method: Polymerase Chain Reaction

Tumor(s): MPN

Uses: diagnosis

Juvenile Polyposis (SMAD4) Sequencing and Deletion/Duplication 2001971

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Tumor(s): colorectal (juvenile polyposis)

Uses: diagnosis

Kaposi Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 0055629

Method: Polymerase Chain Reaction/Fluorescence Monitoring

Tumor(s): Kaposi sarcomas

Uses: diagnosis

Kappa and Lambda Free Light Chains (Bence Jones Protein), Qualitative, Urine 0050161

Method: Qualitative Immunofixation Electrophoresis/Quantitative Nephelometry

Tumor(s): multiple myeloma

Uses: diagnosis; monitoring

Kappa and Lambda Free Light Chains (Bence Jones Protein), Quantitative, Urine 0050618

Method: Qualitative Immunofixation Electrophoresis/Quantitative Nephelometry

Tumor(s): multiple myeloma

Uses: diagnosis; monitoring

Kappa/Lambda Quantitative Free Light Chains with Ratio, Serum 0055167

Method: Quantitative Nephelometry

Tumor(s): multiple myeloma

Uses: diagnosis

Kappa Light Chains by Immunohistochemistry 2003981

Method: Immunohistochemistry

Tumor(s): multiple myeloma

Uses: diagnosis

Keratin 903 (K903) High Molecular Weight by Immunohistochemistry 2003978

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Ki-67, MIB-1, by Immunohistochemistry 2004519

Method: Immunohistochemistry

Tumor(s): lymphomas

Uses: diagnosis

Ki-67 with Interpretation by Immunohistochemistry 2007182

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

KIT (D816V) Mutation by PCR 0040137

Method: Polymerase Chain Reaction

Tumor(s): mastocytosis

Uses: prognosis; predictive information for TKI therapy planning

KIT Mutations in AML by Fragment Analysis and Sequencing 2002437

Method: Polymerase Chain Reaction/Fragment Analysis/Sequencing

Tumor(s): AML

Uses: prognosis

KIT Mutations, Melanoma 2002695

Method: Polymerase Chain Reaction/Sequencing

Tumor(s): melanoma

Uses: prognosis; predictive information for TKI therapy planning

KRAS Mutation Detection 0040248

Method: Polymerase Chain Reaction/Pyrosequencing

Tumor(s): colorectal; NSCLC

Uses: predict response to anti-EGFR therapy resistance

KRAS Mutation Detection with Reflex to BRAF Codon 600 Mutation Detection 2001932

Method: Polymerase Chain Reaction/Pyrosequencing/Fluorescence Resonance Energy Transfer

Tumor(s): colorectal

Uses: preferred test for determining anti-EGFR therapy eligibility

Reflex – if KRAS is not detected, BRAF codon 600 Mutation Detection will be performed

Lactate Dehydrogenase, Serum or Plasma 0020006

Method: Quantitative Enzymatic

Tumor(s): variety of tumors

Uses: diagnosis; monitoring

Lambda Light Chains by Immunohistochemistry 2003984

Method: Immunohistochemistry

Tumor(s): multiple myeloma

Uses: diagnosis

Leukemia/Lymphoma Phenotyping by Flow Cytometry 2008003

Method: Flow Cytometry

Tumor(s): lymphoma; leukemia

Uses: diagnosis; monitoring

Available markers:

T-cell: CD1, CD2, CD3, CD4, CD5, CD7, CD8, TCR alpha-beta, TCR gamma-delta, cytoplasmic CD3
B-cell: CD10, CD19, CD20, CD22, CD23, CD103, kappa, lambda, FMC7, cytoplasmic kappa, cytoplasmic lambda
Myelo/Mono: CD11b, CD13, CD14 (Mo2), CD14 (MY4), CD15, CD33, CD64, CD117, myeloperoxidase
Misc: CD11c, CD16, CD25, CD30, CD34, CD38, CD41, CD42b, CD45, CD56, CD57, CD61, HLA-DR, glycophorin, TdT, bcl-2, ALK-1, CD123, CD138, CD200, CD26, CD45

Leukocyte Alkaline Phosphatase 0049000

Method: Cytochemical Stain

Tumor(s): CML

Uses: screening

Lipid Associated Sialic Acid 0080467

Method: Quantitative Spectrophotometry

Tumor(s): variety of tumors

Uses: diagnosis

Lung Cancer Panel 2008894

Method: Polymerase Chain Reaction/Pyrosequencing/Immunohistochemistry

Tumor(s): lung (adenocarcinoma)

Uses: screening for TKI eligibility

Panel includes EGFR, ALK, and ROS1

Lung Cancer Panel with KRAS 2008895

Method: Polymerase Chain Reaction/Pyrosequencing/Immunohistochemistry

Tumor(s): lung (adenocarcinoma)

Uses: screening for TKI eligibility

Panel includes EGFR, ALK, ROS1, and KRAS

Luteinizing Hormone and Follicle Stimulating Hormone 0070193

Method: Quantitative Electrochemiluminescent Immunoassay

Tumor(s): variety of tumors

Uses: diagnosis

Lymphoma (Aggressive) Panel by FISH 2002650

Method: Fluorescence in situ Hybridization

Tumor(s): lymphoma

Uses: diagnosis

Probes include IGH/BCL2, BCL6, and MYC

Lysozyme, Urine 0050368

Method: Quantitative Radial Immunodiffusion

Tumor(s): leukemia

Uses: diagnosis

Mast Cell Tryptase by Immunohistochemistry 2003993

Method: Immunohistochemistry

Tumor(s): myeloproliferative neoplasm

Uses: diagnosis

MDM2 by Immunohistochemistry 2005848

Method: Immunohistochemistry

Tumor(s): sarcomas

Uses: diagnosis

MDM2 Gene Amplification by FISH 2003016

Method: Fluorescence in situ Hybridization

Tumor(s): sarcomas

Uses: differential diagnosis between well-differentiated/dedifferentiated liposarcoma versus benign lipomatous tumor

Melan A by Immunohistochemistry 2003996

Method: Immunohistochemistry

Tumor(s): melanoma

Uses: diagnosis

Melanoma Antibody, HMB45 by Immunohistochemistry 2003935

Method: Immunohistochemistry

Tumor(s): melanoma

Uses: diagnosis

Metanephrines Fractionated by HPLC-MS/MS, Urine 2007996

Method: Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Tumor(s): pheochromocytoma

Uses: diagnosis; monitoring

Metanephrines, Plasma (Free) 0050184

Method: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Tumor(s): pheochromocytoma

Uses: diagnosis; monitoring

MGMT Methylation Detection by PCR 2009310

Method: Real-Time Polymerase Chain Reaction/Fluorescence Resonance Energy Transfer

Tumor(s): central nervous system

Uses: prognosis

Microsatellite Instability (MSI), HNPCC/Lynch Syndrome, by PCR 0051740

Method: Polymerase Chain Reaction/Fragment Analysis

Tumor(s): Lynch syndrome

Uses: diagnosis

Mismatch Repair by Immunohistochemistry 0049302

Method: Qualitative Immunohistochemistry

Tumor(s): Lynch syndrome; colorectal cancer

Uses: diagnosis

Mismatch Repair by Immunohistochemistry with Reflex to BRAF Codon 600 Mutation and MLH1 Promoter Methylation 2002327

Method: Qualitative Immunohistochemistry/Qualitative Real-time Polymerase Chain Reaction

Tumor(s): Lynch syndrome; colorectal cancer

Uses: diagnosis

Reflex – if MLH1 is abnormal for Mismatch Repair by IHC, then BRAF codon 600 will be added; if BRAF codon 600 is negative, MLH1 Promoter Methylation will be added

Mismatch Repair by Immunohistochemistry with Reflex to MLH1 Promoter Methylation 2005270

Method: Qualitative Immunohistochemistry/Qualitative Real-time Polymerase Chain Reaction

Tumor(s): Lynch syndrome

Uses: diagnosis

Reflex – if MLH1 is abnormal for Mismatch Repair by IHC, then MLH1 Promoter Methylation will be added

MLH1 Promoter Methylation, Paraffin 2002499

Method: Real-Time Polymerase Chain Reaction/Fluorescence Resonance Energy Transfer

Tumor(s): Lynch syndrome

Uses: diagnosis

MLL-AFF1 (MLL-AF4) Translocation, t(4;11) by RT-PCR 0050446

Method: Reverse Transcription Polymerase Chain Reaction

Tumor(s): childhood leukemia

Uses: diagnosis; prognosis

Molar Pregnancy, 16 DNA Markers 0051755

Method: Polymerase Chain Reaction/Fragment Analysis

Tumor(s): gestational trophoblastic 

Uses: diagnosis

MPL codon 515 Mutation Detection by Pyrosequencing, Quantitative 2005545

Method: Polymerase Chain Reaction/Quantitative Pyrosequencing

Tumor(s): MPN

Uses: diagnosis

Muc-1 by Immunohistochemistry 2004002

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Muc-4 by Immunohistochemistry 2004008

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Muc-5AC by Immunohistochemistry 2003999

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Multiple Endocrine Neoplasia Type 1 (MEN1) Sequencing and Deletion/Duplication 2005360

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Tumor(s): MEN1

Uses: diagnosis; risk assessment

Multiple Endocrine Neoplasia Type 2 (MEN2), RET Gene Mutations by Sequencing 0051390

Method: Polymerase Chain Reaction/Sequencing

Tumor(s): MEN2

Uses: diagnosis; risk assessment

Multiple Myeloma Panel by FISH  2002294

Method: Fluorescence in situ Hybridization              

Tumor(s): multiple myeloma

Uses: risk stratification; diagnosis

Panel includes CKS1B (1q gain), ASS1 (+9), CCND1/IGH (IGH/CCND1 fusion or +11), IGH rearrangement, PML (+15) and p53 (17p deletion)

MUM1/IRF4 by Immunohistochemistry 2003975

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis  

Muscle-Specific Actin (MSA) by Immunohistochemistry 2004011

Method: Immunohistochemistry

Tumor(s): sarcomas

Uses: diagnosis

MUTYH-Associated Polyposis (MUTYH) 2 Mutations 2004911

Method: Polymerase Chain Reaction/Sequencing

Tumor(s): colorectal cancer

Uses: diagnosis

MYC (8q24) Gene Rearrangement by FISH 2002345

Method: Fluorescence in situ Hybridization

Tumor(s): lymphoma

Uses: diagnosis

MYCN (N-MYC) Gene Amplification by FISH 2007227

Method: Fluorescence in situ Hybridization

Tumor(s): neuroblastoma

Uses: prognosis

MYD88 L265P Mutation Detection by PCR, Quantitative 2009318

Method: Real-time Polymerase Chain Reaction

Tumor(s): LPL/Waldenström macroglobulinemia

Uses: diagnosis; monitoring

Myelodysplastic Syndrome (MDS) Panel by FISH 2002709

Method: Fluorescence in situ Hybridization

Tumor(s): MDS

Uses: diagnosis; prognosis; monitoring

Panel includes EGR1 (5q del), D7S486 (7q del/-7), CEP8 (+8), D20S108 (20q del)

Myeloperoxidase (MPO) by Immunohistochemistry 2004014

Method: Immunohistochemistry

Tumor(s): AML; MDS

Uses: diagnosis

Myeloproliferative Disorders Panel by FISH 2002360

Method: Fluorescence in situ Hybridization

Tumor(s): MPN

Uses: diagnosis; prognosis

Panel includes BCR/ABL, PDGFRAPDGFRB, and FGFR1

Myeloproliferative Neoplasms Reflex Panel 2007418

Method: Polymerase Chain Reaction/Pyrosequencing

Tumor(s): MPN

Uses: diagnosis

Reflex – if V617F not detected, test reflexes to JAK2 exon 12; if JAK2 exon 12 not detected, test reflexes to MPL codon 515

Myogenin (Myf4) by Immunohistochemistry 2004017

Method: Immunohistochemistry

Tumor(s): any muscular tumor

Uses: diagnosis

Myoglobin by Immunohistochemistry 2004031

Method: Immunohistochemistry

Tumor(s): any muscular tumor

Uses: diagnosis

Myosin by Immunohistochemistry 2004034

Method: Immunohistochemistry

Tumor(s): any muscular tumor

Uses: diagnosis

N-P
 Test Name and NumberRecommended Use

Napsin A by Immunohistochemistry 2008716

Method: Immunohistochemistry

Tumor(s): lung

Uses: diagnosis

Neurofilament by Immunohistochemistry 2004049

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Neuron Specific Enolase 0098198

Method: Quantitative Enzyme-Linked Immunosorbent Assay

Tumor(s): lung (small cell); neuroendocrine

Uses: diagnosis; monitoring

Neuron Specific Enolase, Polyclonal  (NSE P) by Immunohistochemistry 2004052

Method: Immunohistochemistry

Tumor(s): lung (small cell); neuroendocrine

Uses: diagnosis

NMP22, Urine 0080281

Method: Quantitative Enzyme Immunoassay

Tumor(s): bladder

Uses: monitoring; diagnosis

NPM1 Mutation by PCR and Fragment Analysis 0040174

Method: Polymerase Chain Reaction/Fragment Analysis

Tumor(s): AML

Use: prognosis

NRAS Mutation Detection by Pyrosequencing 2003123

Method: Polymerase Chain Reaction/Pyrosequencing

Tumor(s): colorectal; melanoma

Uses: predict response to EGFR-directed therapy

Octamer Transcription Factor-2 (Oct-2) by Immunohistochemistry 2004061

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis  

Octamer Transcription Factor-3 and -4 (Oct 3/4) by Immunohistochemistry 2004058

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

p16 by Immunohistochemistry 2004064

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

p21 (Waf1/Cip 1) by Immunohistochemistry 2004067

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

p504S (AMACR) by Immunohistochemistry 2004076

Method: Immunohistochemistry

Tumor(s): prostate

Uses: diagnosis

P40 by Immunohistochemistry 2010142

Method: Immunohistochemistry

Tumor(s): lung

Uses: diagnosis

p53 by Immunohistochemistry 2004522

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: prognosis

p53 with Interpretation by Immunohistochemistry 0049250

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: prognosis

p63 by Immunohistochemistry 2004073

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Pan Cytokeratin (AE1,3) by Immunohistochemistry 2003433

Method: Immunohistochemistry

Tumor(s): neuroendocrine

Uses: diagnosis

Pancreatic Polypeptide 0099436

Method: Quantitative Radioimmunoassay

Tumor(s): neuroendocrine

Uses: diagnosis; monitoring

Pancreatobiliary FISH 2002461

Method: Fluorescence in situ Hybridization/Computer Assisted Analysis/Microscopy

Tumor(s): pancreatic

Uses: diagnosis

Parathyroid Hormone (PTH) by Immunohistochemistry 2004118

Method: Immunohistochemistry

Tumor(s): parathyroid

Uses: diagnosis

Parathyroid Hormone, Intact with Calcium 0070172

Method: Quantitative Electrochemiluminescent Immunoassay

Tumor(s): parathyroid

Uses: diagnosis; monitoring

Parathyroid Hormone-Related Peptide (PTHrP) 0093014

Method: Quantitative Immunoradiometry

Tumor(s): neuroendocrine; parathyroid

Use: diagnosis; monitoring

PAX2 by Immunohistochemistry 2006291

Method: Immunohistochemistry

Tumor(s): renal cell and high-grade tubo-ovarian serous

Uses: diagnosis

Pax-5 by Immunohistochemistry 2004082

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis  

PAX-FOXO1 and PAX7-FOXO1 Translocations by RT-PCR 0040113

Method: Reverse Transcription Polymerase Chain Reaction/Fluorescence Monitoring

Tumor(s): rhabdomyosarcoma (alveolar subtype)

Uses: diagnosis

PCA3 - Prostate Cancer Biomarker by Transcription-Mediated Amplification 2010102

Method: Transcription-mediated Amplification

Tumor(s): prostate

Uses: diagnosis; monitoring

Peutz-Jeghers Syndrome (STK11) Sequencing and Deletion/Duplication 2008398

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Tumor(s): colorectal (Peutz-Jeghers syndrome)

Uses: diagnosis

PIK3CA Mutation Detection 2004510

Method: Polymerase Chain Reaction/Pyrosequencing

Tumor(s): variety of tumors (most commonly colorectal)

Uses: prognosis

PIN4 Prostate Triple Stain by Immunohistochemistry 2010045

Method: Immunohistochemistry

Tumor(s): prostate

Uses: diagnosis

Components – p504S, p63, 34βE12

Placental Alkaline Phosphatase (PLAP) by Immunohistochemistry 2004097

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

PML/RARA α FISH 2002363

Method: Fluorescence in situ Hybridization

Tumor(s): leukemia (APL)

Uses: diagnosis    

PML-RARA Translocation t(15;17) by RT-PCR, Quantitative 2002871

Method: Reverse Transcription Polymerase Chain Reaction

Tumor(s): leukemia (APL)

Uses: diagnosis; monitoring

Progesterone Receptor (PR) by Immunohistochemistry 2004525

Method: Immunohistochemistry

Tumor(s): breast

Uses: diagnosis

Proinsulin, Intact 0070112

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): neuroendocrine (insulinoma)

Uses: diagnosis

Proinsulin, Intact/Insulin Ratio 0070256

Method: Quantitative Chemiluminescent Immunoassay/Quantitative Chemiluminescent Immunoassay

Tumor(s): neuroendocrine (insulinoma)

Uses: diagnosis

Prolactin by Immunohistochemistry 2004109

Method: Immunohistochemistry

Tumor(s): neuroendocrine

Uses: diagnosis

Prosigna Breast Cancer Prognostic Gene Signature 2010248

Method: Hybridization/gene expression

Tumor(s): breast

Uses: prognosis

Prostate Specific Antigen by Immunohistochemistry 2004112

Method: Immunohistochemistry

Tumor(s): prostate

Uses: diagnosis

Prostate Specific Antigen, Complexed 2002930

Method: Chemiluminescent Immunoassay

Tumor(s): prostate

Uses: diagnosis; monitoring

Prostate Specific Antigen, Free Percentage (includes Free PSA and Total PSA) 0080206

Method: Quantitative Electrochemiluminescent Immunoassay

Tumor(s): prostate

Uses: not preferred for initial screening; preferred test is total prostate specific antigen in conjunction with digital rectal exam

Prostate Specific Antigen, Total 0070121

Method: Quantitative Electrochemiluminescent Immunoassay

Tumor(s): prostate

Uses: screening; staging; prognosis; monitoring; followup

Prostate Specific Antigen, Total with Reflex to Free PSA
(Includes Free Percentage) 0080264

Method: Quantitative Electrochemiluminescent Immunoassay

Tumor(s): prostate

Uses: screening; staging; prognosis; monitoring

Reflex – if PSA Total is between 3.0-10.0 ng/mL, then Free PSA testing will be added

Prostate Specific Antigen, Ultrasensitive 0098581

Method: Quantitative Electrochemiluminescent Immunoassay

Tumor(s): prostate

Uses: screening; staging; prognosis; monitoring

Prostatic Acid Phosphatase (PAP) by Immunohistochemistry 2004079

Method: Immunohistochemistry

Tumor(s): prostate

Uses: diagnosis

Protein Electrophoresis, CSF 0050590

Method: Quantitative Electrophoresis

Tumor(s): multiple myeloma

Uses: diagnosis

Protein Electrophoresis with Reflex to Immunofixation Electrophoresis Monoclonal Protein Detection, Quantitation & Characterization, IgA, IgG, & IgM, Serum 2002109

Method: Quantitative Capillary Electrophoresis/Qualitative Immunofixation Electrophoresis/Quantitative Nephelometry

Tumor(s): multiple myeloma

Uses: diagnosis

Reflex – if patterns from serum protein electrophoresis are monoclonal or suspicious, then Immunofixation Electrophoresis will be added

Protein Gene Product (PGP) 9.5 by Immunohistochemistry 2004091

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

PTEN by Immunohistochemistry 2004115

Method: Immunohistochemistry

Tumor(s): PTEN hamartoma tumor syndrome

Uses: diagnosis

PTEN-Related Disorders (PTEN) Sequencing and Deletion/Duplication 2002470

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Tumor(s): PTEN hamartoma tumor syndrome

Uses: diagnosis

Q-Z
Test Name and NumberRecommended Use

ROS1 with Interpretation by Immunohistochemistry with Reflex to FISH if Equivocal 2008414

Method: Immunohistochemistry

Tumor(s): NSCLC

Uses: determine eligibility for TKI

Reflex – if ROS1 by Immunohistochemistry result is equivocal, then ROS1 by FISH will be added

RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Detection, Quantitative 2010138

Method: Quantitative Reverse Transcription Polymerase Chain Reaction

Tumor(s): AML

Uses: diagnosis; prognosis; monitoring

S-100 Protein by Immunohistochemistry 2004127

Method: Immunohistochemistry

Tumor(s): melanoma

Uses: diagnosis

S-100B Protein, Serum 2001766

Method: Quantitative Enzyme-Linked Immunosorbent Assay

Tumor(s): melanoma

Uses: monitoring; prognosis

SDHB with Interpretation by Immunohistochemistry 2006948

Method: Immunohistochemistry

Tumor(s): neuroendocrine (pheochromocytoma)

Uses: diagnosis

Septin 9 (SEPT9), Methylated DNA Detection by Real-Time PCR 2003243

Method: Polymerase Chain Reaction

Tunor(s): colorectal

Uses: screening

Serotonin, Serum 0080397

Method: Quantitative High Performance Liquid Chromatography

Tumor(s): neuroendocrine (carcinoid)

Uses: diagnosis; monitoring

Serotonin, Whole Blood 0080395

Method: Quantitative High Performance Liquid Chromatography

Tumor(s): neuroendocrine (carcinoid)

Uses: diagnosis; monitoring

Sezary Cell Exam 0049180

Method: Stain

Tumor(s): lymphoma

Uses: diagnosis; flow cytometry is the preferred method of testing due to sensitivity and specificity

Smad4 by Immunohistochemistry 2006403

Method: Immunohistochemistry

Tumor(s): gastrointestinal

Uses: diagnosis

Smooth Muscle Actin (SMA) by Immunohistochemistry 2004130

Method: Immunohistochemistry

Tumor(s): GIST; sarcoma

Uses: diagnosis

Solid Tumor Mutation Panel by Next Generation Sequencing 2007991

Method: Massively Parallel Sequencing

Tumor(s): variety of tumors

Uses: diagnosis

Includes ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL

Soluble Mesothelin-Related Peptides (MESOMARK) 0081284

Method: Quantitative Enzyme-Linked Immunosorbent Assay

Tumor(s): mesothelioma

Uses: monitoring

Somatostatin, Plasma 0098192

Method: Quantitative Extraction/Radioimmunoassay

Tumor(s): neuroendocrine (somatostatinoma)

Uses: diagnosis

Squamous Cell Carcinoma Antigen, Serum 0081054

Method: Quantitative Enzyme-Linked Immunosorbent Assay

Tumor(s): squamous cell; NSCLC; cervical

Uses: monitoring; prognosis; detection of relapse

SS18 (SYT) (18q11) Gene Rearrangement by FISH 2007222

Method: Fluorescence in situ Hybridization

Tumor(s): synovial sarcoma

Uses: diagnosis

Synaptophysin by Immunohistochemistry 2004139

Method: Immunohistochemistry

Tumor(s): neuroendocrine

Uses: diagnosis

SS18-SSX t(X;18) Translocations by RT-PCR 0040114

Method: Reverse Transcription Polymerase Chain Reaction

Tumor(s): synovial sarcoma

Uses: diagnosis

Tartrate-Resistant Acid Phosphatase (TRAP) by Immunohistochemistry 2004160

Method: Immunohistochemistry

Tumor(s): lymphomas

Uses: diagnosis

T-Cell Clonality by Flow Cytometry Analysis of TCR V-Beta 0093199

Method: Flow Cytometry

Tumor(s): T-cell lymphoproliferative disorders

Uses: diagnosis

T-Cell Clonality Screening by PCR 0055567

Method: Polymerase Chain Reaction/Capillary Electrophoresis

Tumor(s): T-cell lymphoproliferative disorders

Uses: diagnosis

T-Cell Clonality by Next Generation Sequencing 2008409

Method: Massive Parallel Sequencing

Tumor(s): T-cell lymphoproliferative disorders

Uses: diagnosis

T-cell Intracytoplasmic Antigen (TIA-1) by Immunohistochemistry 2004148

Method: Immunohistochemistry

Tumor(s): lymphoma

Uses: diagnosis  

TCF3-PBX1 (E2A-PBX1) Translocation, t(1;19) by RT-PCR 0055346

Method: Reverse Transcription Polymerase Chain Reaction/Polymerase Chain Reaction

Tumor(s): ALL

Uses: diagnosis; prognosis   

TdT by Immunohistochemistry 2004142

Method: Immunohistochemistry

Tumor(s): leukemia; lymphoma

Uses: diagnosis  

Thyroglobulin Antibody 0050105

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): thyroid

Uses: diagnosis; monitoring

Thyroglobulin by Immunohistochemistry 2004145

Method: Immunohistochemistry

Tumor(s): thyroid

Uses: diagnosis

Thyroglobulin by LC-MS/MS, Serum or Plasma 2006550

Method: High Performance Liquid Chromatography-Tandem Mass Spectrometry

Tumor(s): thyroid

Uses: monitoring

Thyroglobulin, Fine Needle Aspiration (FNA) 0020753

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): thyroid

Uses: diagnosis

Thyroglobulin, Serum or Plasma with Reflex to LC-MS/MS or CIA 2006685

Method: Quantitative Chemiluminescent Immunoassay/High Performance Chromatography-Tandem Mass

Tumor(s): thyroid

Uses: diagnosis; monitoring

Reflex – reflex testing method (CIA or LC-MS/MS) is determined by the TgAb result

Thyroid Stimulating Hormone 0070145

Method: Quantitative Chemiluminescent Immunoassay

Tumor(s): endocrine (pituitary, thyroid)

Uses: diagnosis; monitoring

Thyroid Transcription Factor (TTF-1) by Immunohistochemistry 2004166

Method: Immunohistochemistry

Tumor(s): endocrine (pituitary, thyroid)

Uses: diagnosis; monitoring

UDP Glucuronosyltransferase 1A1 (UGT1A1) Genotyping 0051332

Method: Polymerase Chain Reaction/Fragment Analysis

Tumor(s): colorectal

Uses: therapy planning

UroVysion FISH 8100600

Method: Fluorescence in situ Hybridization/Computer Assisted Analysis/Microscopy

Tumor(s): bladder

Uses: diagnosis; monitoring

Vanillylmandelic Acid (VMA) and Homovanillic Acid (HVA), Urine 0080470

Method: Quantitative High Performance Liquid Chromatography

Tumor(s): neuroblastoma

Uses: diagnosis; monitoring

Vasoactive Intestinal Peptide 0099435

Method: Quantitative Radioimmunoassay

Tumor(s): neuroendocrine (VIPoma)

Uses: diagnosis; monitoring

Villin by Immunohistochemistry 2004178

Method: Immunohistochemistry

Tumor(s): gastrointestinal

Uses: diagnosis

Vimentin by Immunohistochemistry 2004181

Method: Immunohistochemistry

Tumor(s): variety of tumors

Uses: diagnosis

Wilms Tumor (WT-1), N-terminus by Immunohistochemistry 2004184

Method: Immunohistochemistry

Tumor(s): mesothelioma

Uses: diagnosis    

WT1 Mutation Detection by Sequencing 2005766

Method: Polymerase Chain Reaction/Sequencing

Tumor(s): AML

Uses: diagnosis    

ZAP-70 Analysis by Flow Cytometry 0092392

Method: Flow Cytometry

Tumor(s): CLL

Uses: prognosis